We are live on ! Find out more
RNAC icon

Cartesian Therapeutics
RNAC

98 hedge funds and large institutions have $245M invested in Cartesian Therapeutics in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 38 increasing their positions, 27 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

288% more call options, than puts

Call options by funds: $5.25M | Put options by funds: $1.35M

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

59% more capital invested

Capital invested by funds: $154M → $245M (+$91.3M)

41% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 27

23% more first-time investments, than exits

New positions opened: 16 | Existing positions closed: 13

3% more funds holding

Funds holding: 95 → 98 (+3)

0.04% more ownership

Funds ownership: 1.56% → 1.61% (+0.04%)

Holders
98
Holders Change
+3
Holders Change %
+3.16%
% of All Funds
1.72%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
16
Increased
38
Reduced
27
Closed
13
Calls
$5.25M
Puts
$1.35M
Net Calls
+$3.9M
Net Calls Change
+$4.11M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$6.35M
2
N
Nuveen
North Carolina
+$6.01M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$4.1M
4
ACP
Acuta Capital Partners
California
+$3.41M
5
BlackRock
BlackRock
New York
+$3.18M

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$4.96M
2
BI
BVF Inc
California
-$3.83M
3
Renaissance Technologies
Renaissance Technologies
New York
-$2.84M
4
6CM
683 Capital Management
New York
-$2.17M
5
MP
Mangrove Partners
Connecticut
-$2.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
RJFSA
76
Raymond James Financial Services Advisors
Florida
$81K +$73.6K +593 New
VCA
77
Verdence Capital Advisors
Maryland
$77K – – –
TRCT
78
Tower Research Capital (TRC)
New York
$73K -$134K -1,076 -67%
Victory Capital Management
79
Victory Capital Management
Texas
$60K -$1.61K -13 -3%
HSBC Holdings
80
HSBC Holdings
United Kingdom
$56K +$51.5K +415 New
KWM
81
Kingsview Wealth Management
Oregon
$50K -$1.24K -10 -3%
ASN
82
Advisory Services Network
Georgia
$45K – – –
AF
83
Alerus Financial
North Dakota
$45K +$41.3K +333 New
Legal & General Group
84
Legal & General Group
United Kingdom
$31K -$1.37K -11 -5%
AIP
85
Ameritas Investment Partners
Nebraska
$27K – – –
APA
86
American Portfolios Advisors
New York
$22.6K +$20.7K +167 New
SWM
87
Spire Wealth Management
Virginia
$14K +$12.4K +100 New
Bank of Montreal
88
Bank of Montreal
Ontario, Canada
$11K -$54.1K -436 -83%
PCM
89
Penserra Capital Management
California
$11K -$124 -1 -1%
PAM
90
Panagora Asset Management
Massachusetts
$11K – – –
CG
91
Cutler Group
California
$7K +$497 +4 +8%
VFA
92
Valeo Financial Advisors
Indiana
$2K +$2.11K +17 New
Daiwa Securities Group
93
Daiwa Securities Group
Japan
$1K – – –
Osaic Holdings
94
Osaic Holdings
Arizona
$1K +$745 +6 New
AIG
95
American International Group
New York
$179 +$372 +3 +0.2%
AC
96
Armistice Capital
New York
– -$4.96M -54,533 Closed
6CM
97
683 Capital Management
New York
– -$2.17M -23,821 Closed
MP
98
Mangrove Partners
Connecticut
– -$2.14M -23,522 Closed
JF
99
Jump Financial
Illinois
– -$205K -2,260 Closed
GCP
100
GSA Capital Partners
United Kingdom
– -$185K -2,038 Closed
1 2 3
4
5

RNAC Hedge Fund Activity: Q1 2021 in Review

98 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q1 2021, worth a combined $245M — up 59% from $154M a quarter earlier.

Buyers outnumbered sellers: 16 funds opened new RNAC positions and 13 closed out — a net gain of 3 holders — while 38 added to existing stakes and 27 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $6.35M. The largest seller was Armistice Capital, exiting entirely with an estimated $4.96M sold.

  • 98 institutional investors held Cartesian Therapeutics (RNAC) as of Q1 2021, up from 95 in Q4 2020.
  • Funds reported $245M of Cartesian Therapeutics stock for Q1 2021, up 59% quarter-over-quarter.
  • 16 funds opened new Cartesian Therapeutics positions in Q1 2021 and 13 closed out, a net change of +3 holders.
  • The largest Cartesian Therapeutics buyer in Q1 2021 was Goldman Sachs, an estimated $6.35M added.
  • The largest Cartesian Therapeutics seller in Q1 2021 was Armistice Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q1 2021.